JP2014534265A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534265A5
JP2014534265A5 JP2014543618A JP2014543618A JP2014534265A5 JP 2014534265 A5 JP2014534265 A5 JP 2014534265A5 JP 2014543618 A JP2014543618 A JP 2014543618A JP 2014543618 A JP2014543618 A JP 2014543618A JP 2014534265 A5 JP2014534265 A5 JP 2014534265A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
amino acid
acid sequence
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014543618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534265A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066795 external-priority patent/WO2013082116A1/en
Publication of JP2014534265A publication Critical patent/JP2014534265A/ja
Publication of JP2014534265A5 publication Critical patent/JP2014534265A5/ja
Pending legal-status Critical Current

Links

JP2014543618A 2011-11-28 2012-11-28 インスリンアミノ酸配列を含む治療薬 Pending JP2014534265A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563985P 2011-11-28 2011-11-28
US61/563,985 2011-11-28
PCT/US2012/066795 WO2013082116A1 (en) 2011-11-28 2012-11-28 Therapeutic agents comprising insulin amino acid sequences

Publications (2)

Publication Number Publication Date
JP2014534265A JP2014534265A (ja) 2014-12-18
JP2014534265A5 true JP2014534265A5 (enExample) 2016-01-21

Family

ID=48536000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014543618A Pending JP2014534265A (ja) 2011-11-28 2012-11-28 インスリンアミノ酸配列を含む治療薬

Country Status (14)

Country Link
US (2) US20130150291A1 (enExample)
EP (1) EP2785367A4 (enExample)
JP (1) JP2014534265A (enExample)
KR (1) KR20140103985A (enExample)
CN (1) CN104080473A (enExample)
AU (1) AU2012346058A1 (enExample)
BR (1) BR112014012789A2 (enExample)
CA (1) CA2856967A1 (enExample)
HK (1) HK1202067A1 (enExample)
IL (1) IL232781A0 (enExample)
MX (1) MX2014006391A (enExample)
RU (1) RU2014126244A (enExample)
SG (1) SG11201402661TA (enExample)
WO (1) WO2013082116A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
WO2014081849A1 (en) 2012-11-20 2014-05-30 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
JP2016505627A (ja) * 2013-01-15 2016-02-25 フェーズバイオ ファーマシューティカルズ,インコーポレイテッド 治療剤、組成物、および血糖コントロールのための方法
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
WO2015178466A1 (ja) * 2014-05-21 2015-11-26 味の素株式会社 フィブロイン様タンパク質の製造法
EP3220936A4 (en) * 2014-11-21 2018-08-22 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
CN114652817B (zh) 2015-02-09 2026-04-17 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
EP3124495A1 (en) * 2015-07-31 2017-02-01 Centre National de la Recherche Scientifique (C.N.R.S.) Derivatives of elastin-like polypeptides and uses thereof
EA037478B1 (ru) 2015-08-04 2021-04-01 Дьюк Юниверсити Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
CN105061566A (zh) * 2015-09-05 2015-11-18 苏州普罗达生物科技有限公司 拟胰岛素多肽及其应用
KR20170036643A (ko) * 2015-09-24 2017-04-03 한미약품 주식회사 인슐린의 제조 방법
KR101815080B1 (ko) 2015-11-03 2018-01-04 재단법인대구경북과학기술원 췌장소도세포 및 엘라스틴 유사 인공 세포외 기질을 포함하는 당뇨병 치료용 약학적 조성물
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CN108463242A (zh) 2016-03-02 2018-08-28 梅尔兹制药公司 包含肉毒杆菌毒素的组合物
WO2017189860A1 (en) 2016-04-27 2017-11-02 The Regents Of The University Of California Preparation of functional homocysteine residues in polypeptides and peptides
MX2018013546A (es) 2016-05-06 2019-04-22 Phasebio Pharmaceuticals Inc Proteinas de fusion de elp para liberacion controlada y sostenida.
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
JP2020500150A (ja) * 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
US11220467B2 (en) 2017-01-11 2022-01-11 Recycle Track Systems, Inc. Indoor food waste fermentation and recycling process
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US12594347B2 (en) 2018-09-07 2026-04-07 Duke University Nanoparticulate drug delivery systems
CN111939244B (zh) 2019-05-14 2024-08-06 阿莫生命科学有限公司 用于预防或治疗糖尿病并发症的药物组合物
KR102456958B1 (ko) * 2019-05-14 2022-10-21 강원대학교 산학협력단 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US12435116B2 (en) 2019-10-16 2025-10-07 Clarence Hurt Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
EP4071178A4 (en) * 2019-12-06 2024-10-09 Ajinomoto Co., Inc. METHOD FOR PREPARING A PEPTIDE WITH PHYSIOLOGICAL ACTIVITY AND A PEPTIDE WITH A SHORT LINKER

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2230727T3 (es) * 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
WO2007073486A2 (en) * 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CN101495136A (zh) * 2006-02-15 2009-07-29 英克隆系统公司 抗体配制品
CN101616685B (zh) * 2006-03-06 2013-07-24 阿穆尼克斯运营公司 非结构化重组聚合物和其应用
CN102131516B (zh) * 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
WO2010014689A1 (en) * 2008-07-29 2010-02-04 Phasebio Pharmaceuticals, Inc. Pharmaceutical formulations comprising elastin-like proteins
NZ597964A (en) * 2009-07-31 2014-04-30 Sanofi Aventis Deutschland Long acting insulin composition
US9029505B2 (en) * 2009-08-14 2015-05-12 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides

Similar Documents

Publication Publication Date Title
JP2014534265A5 (enExample)
RU2014126244A (ru) Лекарственные средства, содержащие аминокислотные последовательности инсулина
CN102026666B (zh) 促胰岛素肽缀合物制剂
JP2010031018A5 (enExample)
JP6084215B2 (ja) ポリエチレングリコールまたはその誘導体でpeg化されたエキセンジン−4類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物
RU2434640C2 (ru) Лечение метастатического рака молочной железы
CA2729938A1 (en) New insulin analogues of prolonged activity
ES2614287T3 (es) Lixisenatida como terapia adicional a la insulina basal en diabetes de tipo 2
CN102643339B (zh) 一种glp-1类似物、制备方法及其应用
JP2021521230A5 (enExample)
ES2932498T3 (es) Composiciones que comprenden el péptido WKDEAGKPLVK
ES2723887T3 (es) Formulación de relación fija de insulina glargina/lixisenatida
MY158627A (en) Halogen-stabilized insulin
WO2012130136A1 (zh) 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
JP2016516076A5 (enExample)
JP2014526441A5 (enExample)
UA95488C2 (ru) Концентрированный раствор метотрексата для подкожного введения
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
ES2971959T3 (es) Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua
JP2017529326A5 (enExample)
CN103665148A (zh) 一种可口服给药的降糖多肽及其制法和用途
JP2019527053A5 (enExample)
JP2014506579A5 (enExample)
CN102552883B (zh) 一种多肽复合物、药物组合物、其制备方法和应用
PT2285416E (pt) Conjugados para o tratamento de mesotelioma